{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:47:59Z","timestamp":1789426079563,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B6003074"],"award-info":[{"award-number":["2018R1A2B6003074"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11481-020-09943-6","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T21:02:45Z","timestamp":1594846965000},"page":"470-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Potent PDE10A Inhibitor MP-10 (PF-2545920) Suppresses Microglial Activation in LPS-Induced Neuroinflammation and MPTP-Induced Parkinson\u2019s Disease Mouse Models"],"prefix":"10.1007","volume":"16","author":[{"given":"Do-Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Hyun","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1889-8739","authenticated-orcid":false,"given":"Hee-Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"9943_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00044.2005","volume":"87","author":"K Bedard","year":"2007","unstructured":"Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245\u2013313","journal-title":"Physiol Rev"},{"key":"9943_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00004850-198807000-00006","volume":"3","author":"A Bertolino","year":"1988","unstructured":"Bertolino A, Crippa D, Dio SD, Fichte K, Musmeci G, Porro V, Sastre Y, Hermande M, Schratzer M (1988) Rolipram versus imipramine in inpatients with major, \u201cminor\u201d or atypical depressive disorder: a double blinded-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol 3:245\u2013253","journal-title":"Int Clin Psychopharmacol"},{"key":"9943_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jnr.490310405","volume":"31","author":"V Bocchini","year":"1992","unstructured":"Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 31:616\u2013621","journal-title":"J Neurosci Res"},{"key":"9943_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1742-2094-11-98","volume":"11","author":"JD Cherry","year":"2014","unstructured":"Cherry JD, Olschowka JA, O\u2019Banion MK (2014) Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 11:98","journal-title":"J Neuroinflammation"},{"key":"9943_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4062\/biomolther.2018.202","volume":"27","author":"SJ Cho","year":"2019","unstructured":"Cho SJ, Kang KA, Piao MJ, Ryu YS, Fernando PDSM, Zhen AX, Hyun YJ, Ahn MJ, Kang HK, Hyun JW (2019) 7,8-dihydroxyflavone protects high glucose-damaged neuronal cells against oxidative stress. Biomol Ther 27:85\u201391","journal-title":"Biomol Ther"},{"key":"9943_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.neuropharm.2012.01.028","volume":"62","author":"LM Collins","year":"2012","unstructured":"Collins LM, Toulouse A, Connor TJ, Nolan YM (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson\u2019s disease. Neuropharmacology 62:2154\u20132168","journal-title":"Neuropharmacology"},{"key":"9943_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00002826-200305000-00008","volume":"26","author":"S Cristina","year":"2003","unstructured":"Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C (2003) High-dose ropinirole in advanced Parkinson\u2019s disease with severe dyskinesias. Clin Neuropharmacol 26:146\u2013150","journal-title":"Clin Neuropharmacol"},{"key":"9943_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.12703\/P5-53","volume":"5","author":"JC Cronk","year":"2013","unstructured":"Cronk JC, Kipnis J (2013) Microglia- the brain\u2019s busy bees. F1000 Prime Rep 5:53","journal-title":"F1000 Prime Rep"},{"key":"9943_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11481-006-9015-5","volume":"1","author":"GA Garden","year":"2006","unstructured":"Garden GA, Moller T (2006) Microglia biology in health and disease. J NeuroImmune Pharmacol 1:127\u2013137","journal-title":"J NeuroImmune Pharmacol"},{"key":"9943_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12974-015-0463-9","volume":"13","author":"M Ghosh","year":"2016","unstructured":"Ghosh M, Xu Y, Pearse DD (2016) Cyclic AMP is a key regulator of M1 and M2a phenotype conversion of microglia in the presence of Th2 cytokines. J Neuroinflammation 13:9","journal-title":"J Neuroinflammation"},{"key":"9943_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","volume":"28","author":"M Giorgi","year":"2008","unstructured":"Giorgi M, D\u2019Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G (2008) Lowered cAMP and cGMP signaling in the brain during levodopa-induced dyskinesia in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28:941\u2013950","journal-title":"Eur J Neurosci"},{"key":"9943_CR12","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918\u2013934","journal-title":"Cell"},{"issue":"2","key":"9943_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1124\/jpet.109.155994","volume":"331","author":"SM Grauer","year":"2009","unstructured":"Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331(2):574\u2013590","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"9943_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ijnp\/pyw030","volume":"19","author":"PRA Heckman","year":"2016","unstructured":"Heckman PRA, van Duinen MA, Bollen EPP, Nishi A, Wennogle LP, Blokland A, Prickaerts J (2016) Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol 19(10):1\u201316","journal-title":"Int J Neuropsychopharmacol"},{"key":"9943_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/1389450119666180808105056","volume":"20","author":"A Jankowska","year":"2019","unstructured":"Jankowska A, Swierczek A, Wyska E, Gawalska A, Bucki A, Pawlowski M, Chlon-Rzepa G (2019) Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 1: overview of the chemical and biological research. Curr Drug Targets 20:122\u2013143","journal-title":"Curr Drug Targets"},{"key":"9943_CR16","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1471-4159.2010.07075.x","volume":"115","author":"JS Jung","year":"2010","unstructured":"Jung JS, Shin JA, Park EM et al (2010) Anti-inflammatory mechanism of ginsenoside Rh1 in lipopolysaccharide-stimulated microglia: critical role of the protein kinase A pathway and hemeoxygenase-1 expression. J Neurochem 115:1668\u20131680","journal-title":"J Neurochem"},{"key":"9943_CR17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/ijms18040696","volume":"18","author":"EP Knott","year":"2017","unstructured":"Knott EP, Assi M, Rao SN, Ghosh M, Pearse DD (2017) Phosphodiesterase inhibitors as therapeutic approach to neuroprotection and repair. Int J Mol Sci 18:696","journal-title":"Int J Mol Sci"},{"key":"9943_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/j.1471-4159.2008.05864.x","volume":"108","author":"B Lee","year":"2009","unstructured":"Lee B, Cao R, Choi YS, Cho HY, Rhee AD, Hah CK, Hoy KR, Obrietan K (2009) The CREB\/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J Neurochem 108:1251\u20131265","journal-title":"J Neurochem"},{"key":"9943_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4049\/jimmunol.0903480","volume":"185","author":"EJ Lee","year":"2010","unstructured":"Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, Junn E, Kim HS (2010) \u03b1-Synuclein activates microglia by inducing the expressions of matrix metalloproteases and the subsequent activation of protease-activated receptor-1. J Immunol 185:615\u2013623","journal-title":"J Immunol"},{"key":"9943_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","volume":"10","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Bae EJ, Lee SJ (2014) Extracellular \u03b1-synuclein \u2013 a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 10:92\u201398","journal-title":"Nat Rev Neurol"},{"key":"9943_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12974-015-0355-z","volume":"12","author":"EJ Lee","year":"2015","unstructured":"Lee EJ, Ko HM, Jeong YH, Park EM, Kim HS (2015) \u03b2-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. J Neuroinflammation 12:133","journal-title":"J Neuroinflammation"},{"key":"9943_CR22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12974-019-1649-3","volume":"16","author":"YY Lee","year":"2019","unstructured":"Lee YY, Park JS, Leem YH, Park JE, Kim DY, Choi YH, Park EM, Kang JL, Kim HS (2019) The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson\u2019s disease mouse models. J Neuroinflammation 16:246","journal-title":"J Neuroinflammation"},{"issue":"2","key":"9943_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/syn.21792","volume":"69","author":"SF Lin","year":"2015","unstructured":"Lin SF, Labaree D, Chen MK, Holden D, Gallezot JD, Kapinos M, Teng JK, Najafzadeh S, Plisson C, Rabiner EA, Gunn RN, Carson RE, Huang Y (2015) Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A (PDE10A): PET imaging study in rhesus monkeys and brain tissue metabolite analysis. Synapse 69(2):86\u201395","journal-title":"Synapse"},{"key":"9943_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fncel.2019.00514","volume":"13","author":"CY Liu","year":"2019","unstructured":"Liu CY, Wang X, Liu C, Zhang HL (2019) Pharmacological targeting of microglial activation: new therapeutic approach. Front Cell Neurosci 13:514","journal-title":"Front Cell Neurosci"},{"key":"9943_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.brainres.2007.05.030","volume":"1160","author":"N Matsukawa","year":"2007","unstructured":"Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan CV (2007) Overexpression of D2\/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Res 1160:113\u2013123","journal-title":"Brain Res"},{"key":"9943_CR26","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1093\/brain\/awv219","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F, Foltynie T, Reis Marques T, Muhlert N, Tziortzi AC, Searle GE, Natesan S, Kapur S, Rabiner EA, Gunn RN, Piccini P, Politis M (2015) Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson\u2019s disease. Brain 138:3003\u20133015","journal-title":"Brain"},{"issue":"4","key":"9943_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FBP.0000000000000201","volume":"27","author":"A Nikiforuk","year":"2016","unstructured":"Nikiforuk A, Potasiewicz A, Rafa D, Drescher K, Bespalov A, Popik P (2016) The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors. Behav Pharmacol 27(4):331\u2013338","journal-title":"Behav Pharmacol"},{"key":"9943_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4062\/biomolther.2018.234","volume":"27","author":"JS Park","year":"2019","unstructured":"Park JS, Leem YH, Park JE, Kim DY, Kim HS (2019) Neuroprotective effect of \u03b2-lapachone in MPTP-induced Parkinson\u2019s disease mouse model: involvement of astroglial p-AMPK\/Nrf2\/HO-1 signaling pathways. Biomol Ther 27:178\u2013184","journal-title":"Biomol Ther"},{"key":"9943_CR29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/glia.22986","volume":"64","author":"DD Pearse","year":"2016","unstructured":"Pearse DD, Hughes ZA (2016) PDE4B as a microglia target to reduce neuroinflammation. Glia 64:1698\u20131709","journal-title":"Glia"},{"key":"9943_CR30","doi-asserted-by":"publisher","first-page":"940207","DOI":"10.1155\/2015\/940207","volume":"2015","author":"CA Peixoto","year":"2015","unstructured":"Peixoto CA, Nunes AK, Garcia-Osta A (2015) Phosphdiesterase-5 inhibitors: action on the signaling pathways of neuroinflammation and neurodegeneration and cognition. Mediat Inflamm 2015:940207","journal-title":"Mediat Inflamm"},{"key":"9943_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00401-010-0795-6","volume":"121","author":"P Pifarre","year":"2011","unstructured":"Pifarre P, Prado J, Baltrons MA, Giralt M, Gabarro P, Feinstein DL, Hidalgo J, Garcia A (2011) Sidenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol 121:499\u2013508","journal-title":"Acta Neuropathol"},{"issue":"6","key":"9943_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.nucmedbio.2011.02.005","volume":"38","author":"C Plisson","year":"2011","unstructured":"Plisson C, Salinas C, Weinzimmer D, Labaree D, Lin SF, Ding YS, Jakobsen S, Smith PW, Eiji K, Carson RE, Gunn RN, Rabiner EA (2011) Radiosynthesis and in vivo evaluation of [11C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl Med Biol 38(6):875\u2013884","journal-title":"Nucl Med Biol"},{"key":"9943_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jchemneu.2015.12.002","volume":"71","author":"SN Rai","year":"2016","unstructured":"Rai SN, Yadav SK, Singh D, Singh SP (2016) Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. J Chem Neuroanat 71:41\u201349","journal-title":"J Chem Neuroanat"},{"key":"9943_CR34","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14728222.2013.818656","volume":"17","author":"W Richter","year":"2013","unstructured":"Richter W, Menniti FS, Zhang HT, Conti M (2013) PDE4 as a target for cognition enhancement. Expert Opin Ther Targets 17:1011\u20131027","journal-title":"Expert Opin Ther Targets"},{"key":"9943_CR35","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1021\/cb500671j","volume":"9","author":"JP Schulke","year":"2014","unstructured":"Schulke JP, McAllister LA, Geoghegan KF, Parikh V, Chappie TA, Verhoest PR, Schmidt CJ, Johnson DS, Brandon NJ (2014) Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment. ACS Chem Biol 9:2823\u20132832","journal-title":"ACS Chem Biol"},{"key":"9943_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fnagi.2017.00139","volume":"9","author":"GH Song","year":"2017","unstructured":"Song GH, Suk K (2017) Pharmacological modulation of functional phenotypes of microglia in neurodegenerative diseases. Front Aging Neurosci 9:139","journal-title":"Front Aging Neurosci"},{"key":"9943_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fnagi.2017.00176","volume":"9","author":"SR Subramaniam","year":"2017","unstructured":"Subramaniam SR, Federoff HJ (2017) Targeting microglial activation states as a therapeutic avenue in Parkinson\u2019s disease. Front Aging Neurosci 9:176","journal-title":"Front Aging Neurosci"},{"key":"9943_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"1","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 1:318\u2013324","journal-title":"J Neurochem"},{"key":"9943_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2174\/1381612820666140826114744","volume":"21","author":"LS Wilson","year":"2015","unstructured":"Wilson LS, Brandon NJ (2015) Emerging biology of PDE10A. Curr Pharm Des 21:378\u2013388","journal-title":"Curr Pharm Des"},{"key":"9943_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.neuropharm.2015.08.008","volume":"99","author":"JM Wilson","year":"2015","unstructured":"Wilson JM, Ogden AML, Loomis S, Gilmour G, Baucum AJ 2nd, Belecky-Adams TL, Merchant KM (2015) Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum. Neuropharmacology 99:379\u2013386","journal-title":"Neuropharmacology"},{"key":"9943_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0929867325666180309110629","volume":"25","author":"A Zagorska","year":"2018","unstructured":"Zagorska A, Partyka A, Bucki A, Gawalska A, Czopek A, Pawlowski M (2018) Phosphodiesterase 10 inhibitors \u2013 novel perspectives for psychiatric and neurodegenerative drug discovery. Curr Med Chem 25:1\u201327","journal-title":"Curr Med Chem"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-020-09943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-020-09943-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-020-09943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T23:49:43Z","timestamp":1626306583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-020-09943-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9943"],"URL":"https:\/\/doi.org\/10.1007\/s11481-020-09943-6","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}